Positive Phase 1 JADE101 data and accelerated pipeline timelines (JADE301 Phase 1 ahead of plan) are strong catalysts. Monitor interim Phase 2 JADE101 data in 2027 and Phase 1 JADE301 initiation for further de-risking. The $172.5M offering and $461M cash position reduce near-term dilution risk, but widening losses and lack of revenue remain headwinds for a clinical-stage biotech.
Price Chart
Executive Summary
Jade Biosciences reported Q2 2026 financial results with a net loss of $55.8M, wider than the $32.1M loss in Q2 2025, driven by increased R&D and G&A spending. The clinical update highlighted positive interim Phase 1 data for JADE101 in IgA nephropathy, initiation of Phase 2 and planned Phase 3 trials, and the unveiling of JADE301 for dermatomyositis. The $461.2M cash position provides runway into Q4 2028, supported by a $172.5M public offering.
Key Financial Metrics
Key Facts
- Positive interim Phase 1 JADE101 data showed mean IgA reductions of ~70% after a single 700mg dose, supporting every-12-week subcutaneous dosing.
- Phase 2 JUNIPER trial of JADE101 in IgAN underway; interim data expected 2027; registrational Phase 3 planned first half 2027.
- JADE301 unveiled for dermatomyositis with YTE half-life extension; Phase 1 in healthy volunteers expected Q4 2026, interim data 2H 2027.
- JADE201 Phase 1 RA trial dosing started; interim data expected 2027.
- Cash, equivalents, and investments: $461.2M as of 6/30/2026, providing runway into Q4 2028.
- Net loss widened to $55.8M in Q2 2026 vs $32.1M in Q2 2025 due to higher R&D ($50.1M vs $22.5M) and G&A ($8.9M vs $5.2M).
- GAAP EPS: -$0.76 per common share for Q2 2026 vs -$0.86 year-ago.
Financial Impact
GAAP EPS miss of -$0.76 vs consensus of -$0.54; R&D spend doubling YoY to $50.1M; net loss increased 74% to $55.8M.
Risk Factors
- No revenue; cash burn rate is high ($58.9M quarterly operating loss); runway assumes no new spending beyond current plan.
- Clinical risk: Phase 2/3 JADE101 and Phase 1 JADE301/JADE201 may fail to replicate interim efficacy/safety.
- Regulatory risk: FDA could impose additional requirements before Phase 3 registrational trial.
- Dilution risk: $172.5M offering suggests potential future cap raises if cash burn accelerates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341688 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $14.52 | awaiting T+5 | — | $14.74 (+1.52%) |
Sep 30, 2026 27d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.74 (+4.91%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.74 (−32.17%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.74 (−32.17%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.74 (+1.60%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.74 (+12.99%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.74 (+12.99%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.74 (+16.91%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.74 (+16.91%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.74 (+16.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers